30 closest matches · ranked by relevance
Gastrointestinal Lesions · Signs and Symptoms, Digestive
Primary: GI Mucosal Lesions Change and Clinical Symptoms Using The Gastrointestinal Symptom Rating Scale (GSRS) Score — 2.99; 2.19 GSRS score — p=0.05
Fabry's Disease
Primary: Gastric Emptying Transit Time Measured Via SmartPill Study — 2.9; 2.8 Hours
High Risk Polyposis Syndrome · Distal Colonic Lesions · Colorectal Polyps
Primary: Number of Neoplastic Lesions Detected — 3 Lesions
Gastrointestinal Stromal Tumors
Primary: Number of Patients Who Survived — 5 Participants
Irritable Bowel Syndrome · Small Intestinal Bacterial Overgrowth
Primary: Global Improvement Scale — 4.3; 4.3 units on a scale — p=0.26
Postural Tachycardia Syndrome
Primary: C-peptide Levels After Oral Glucose Tolerance Test — 40.6; 23.2 pg/mL
Large Polyps in the Gastrointestinal Tract
Primary: Duration of the Submucosal Cushion
Capsule Endoscopy
Primary: Circumferential Visualization of the Z-line — 0; 5; 5; 7 Participants
Barrett Syndrome · Barrett's Syndrome · Barrett's Esophagus
Primary: Number of Barrett's Esophagus (BE) Participants With a Composite Outcome of "Optimally Treated" — 16; 16 participants
Esophageal Lesion
Primary: Number of Participants With Esophageal Lesions Identified Using Capsule Endoscopy — 15 Participants
Esophageal Neoplasms
Primary: Accuracy — 89; 70 Percentage of accuracy
Gastro Intestinal Bleeding · Hematemesis · Melena
Primary: Rate of Detection of Bleeding — 11; 11 Participants
Gastrointestinal and Gynecologic Malignancies
Primary: Rate of Detectable Peritoneal Metastases — 0; 2 percentage of lesions
Colon Cancer
Primary: Total Number of Serrated Lesions Proximal to the Sigmoid Colon — 204; 158; 95; 59 Serrated Lesions
Polyp of Colon · Fistula
Primary: Time to Closure — 23.3; 18.4 minutes
Gastrointestinal Cancer
Primary: Serious Adverse Events — 0 Participants
Gastrointestinal Diseases
Primary: Device Success Defined as the Ability to Record Myoelectric Signals in Study Subjects. — 88 participants
Colorectal Lesion
Primary: Accuracy, Sensitivity, and Specificity for Differentiating Neoplastic and Non-neoplastic Lesions — 94.3; 98.0; 92.0 percentage of lesions
Upper GI Bleeding
Primary: Number of Participants With True Positive Results — 3 Participants
Autoimmune Disease
Primary: Changes in GI Symptom Severity After Conversion From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) — 2.28; 2.02; -0.28 Scores on a scale
Dyspepsia · Diabetes Mellitus With Gastrointestinal Symptoms
Primary: Mean Intestinal Chemosensitivity to Lipids Perfusion — 0.22; 0.36; 0.55; 0.65 score on a scale — p=0.06
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
Inflammatory Bowel Diseases
Primary: Mucosal Impedance Values — 1139; 849; 891; 783 ohms
Cystic Fibrosis
Primary: Number of Participants Who Fully Completed at Least One ePRO — 133; 196; 130; 194 Participants
Ileus · Post-Operative Adhesions
Primary: Change From Baseline in Extent and Severity of Intra-abdominal Adhesions Among Subjects Treated With LB1148 or Placebo — 20.3; 4.3; 4.0; 8.5 total extent and severity…
Aging · Hyperthermia
Primary: Log Lactulose/Rhamnose Following Control Trial — 0.97; 0.79 Ratio
Morbid Obesity
Primary: Number of Patients With Transmitted Light Intensity to Gastric Wall Thickness) — 10 Participants
Gastric Cancer · Gastric Neoplasms
Primary: Percentage of Participants With Detectable Confocal Endoscopic Microscopy (CEM) w/Greater Sensitivity for Detection of Signet Ring Cells (SRC)Foci in Cadherin-1 (CDH1)…
Idiopathic Parkinson's Disease
Primary: Change From Baseline to Visit 3 in the Assessment of Intensity of Gastrointestinal (GI) Complaints for Any Reason as Per Visual Analogue Scale (VAS) — -26.8 millimeter…
Upper Gastrointestinal Mucosal Damage
Primary: Incidence of Subjects With Gastroduodenal Erosions and Ulcers. — 72; 54; 19; 36 participants